SCHEMBL4471342

SCHEMBL4471342

COc1cc2c(Oc3ccc(Nc4ccc(C(C)(C)C)cc4)c(F)c3)ccnc2cc1OCCN1CCOCC1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR2 P21802 12/20 0.83
AXL P30530 3/20 0.57
KDR P35968 4/20 0.56
MET P08581 2/20 0.56
PDGFRB P09619 1/20 0.55
KIT P10721 1/20 0.55
PDGFRA P16234 1/20 0.55
EGFR P00533 1/20 0.55
FGFR1 P11362 1/20 0.55
FLT1 P17948 1/20 0.55
FLT4 P35916 1/20 0.55
AURKA O14965 1/20 0.54
RPS6KA5 O75582 1/20 0.54
LCK P06239 1/20 0.54
PIM1 P11309 1/20 0.54
HGF P14210 1/20 0.54
RPS6KB1 P23443 1/20 0.54
MAPK9 P45984 1/20 0.54
TEK Q02763 1/20 0.54
MST1R Q04912 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4485078 0.91 FGFR2 (1.00) FGFR2AXLKDRMETPDGFRB
SCHEMBL4478724 0.91 FGFR2 (1.00) FGFR2AXLKDRMETPDGFRB
SCHEMBL4468108 0.90 FGFR2 (0.72) FGFR2AXLKDRMETPDGFRB
SCHEMBL4486864 0.89 FGFR2 (0.84) FGFR2AXLKDRMETPDGFRB
SCHEMBL4489376 0.88 FGFR2 (0.76) FGFR2AXLKDRMETPDGFRB
SCHEMBL4476247 0.87 FGFR2 (0.92) FGFR2AXLKDRMETPDGFRB
SCHEMBL4488788 0.86 FGFR2 (0.70) FGFR2AXLKDRMETPDGFRB
SCHEMBL4465059 0.86 FGFR2 (0.91) FGFR2AXLKDRMETPDGFRB
SCHEMBL4474144 0.86 FGFR2 (1.00) FGFR2AXLKDRPDGFRBKIT
SCHEMBL4486405 0.85 FGFR2 (0.78) FGFR2AXLKDRMETPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US claimed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2005-03-03 US disclosed
EP-1447405-A1 QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING AUTO-PHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS KIRIN BEER KABUSHIKI KAISHA (JP) 2004-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors FGFR1, FGFR2, FGFR3 FGFR2 2/4885AXL 40/4885KDR 211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.